NASDAQ:BBI Brickell Biotech (BBI) Stock Forecast, Price & News $0.98 +0.04 (+4.26%) (As of 09/22/2023 ET) Add Compare Share Share Today's Range$0.90▼$1.0050-Day Range$0.58▼$0.9852-Week Range$2.21▼$37.35Volume621,334 shsAverage Volume206,730 shsMarket Capitalization$2.82 millionP/E RatioN/ADividend YieldN/APrice TargetN/A ProfileProfileChartCompetitorsFinancialsInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaProfileChartCompetitorsFinancialsInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media About Brickell Biotech (NASDAQ:BBI) StockBrickell Biotech, Inc., a clinical-stage pharmaceutical company, engages in the development of various prescription therapeutics for the treatment of autoimmune, inflammatory, and other debilitating diseases in the United States. The company develops sofpironium bromide, which has completed Phase III clinical trials for the treatment of primary axillary hyperhidrosis; BBI-02, an oral DYRK1A inhibitor for the treatment of autoimmune and inflammatory diseases; and BBI-10, a covalent stimulator of interferon genes inhibitor for the potential treatment of autoinflammatory and rare genetic diseases, as well as next-generation kinase inhibitors. It has license and collaboration agreements with Carna Biosciences, Inc., Voronoi Inc., Bodor Laboratories, Inc. and Dr. Nicholas S. Bodor, and AnGes, Inc. The company was founded in 2009 and is headquartered in Boulder, Colorado.Read More BBI Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart BBI Stock News HeadlinesAugust 27, 2023 | dailymail.co.ukPaul Simon and Edie Brickell's daughter speaks out following parents' arrestApril 25, 2023 | bizjournals.comSeattle Biotech NewsSeptember 24, 2023 | Behind the Markets (Ad)BREAKING: Tiny biotech successfully treats blindnessThere's a tiny biotech in Cambridge that's using a breakthrough technology to treat blindness. This company has already shown success in human trials... And Our research shows that anyone who gets in today could see a 46,751% return.April 10, 2023 | marketwatch.comNuclear Receptor ROR-Gamma Market Size by 2030March 29, 2023 | travel.usnews.comBrickell City CentreMarch 24, 2023 | bizjournals.comBiotech NewsMarch 18, 2023 | techcrunch.com5 strategies for biotech startups to outlast a market downturnMarch 14, 2023 | marketwatch.comNuclear Receptor ROR-Gamma Market Application, Product, Sales and Forecast 2023-2028September 24, 2023 | Behind the Markets (Ad)66,000% upside on tiny biotech?The Wall Street Journal reports that this medical breakthrough is "Transforming Medicine." One analyst calculated that it could be worth $1 Trillion, making the upside potential of this small-cap 66,000% above today's price.February 27, 2023 | finance.yahoo.comWhat Sunzen Biotech Berhad's (KLSE:SUNZEN) P/E Is Not Telling YouFebruary 27, 2023 | techcrunch.comBiotech proved a surprisingly bright spot in 2022’s startup correctionFebruary 21, 2023 | msn.comPaul Simon Was 50 When He Married a 26-Year-Old Edie BrickellFebruary 19, 2023 | cnbc.comThis biotech hedge fund has elite clients like Yale’s endowment, Tisch. Here are its top betsFebruary 10, 2023 | benzinga.comBest Biotech Penny StocksJanuary 13, 2023 | markets.businessinsider.comVERO Biotech Raises $30 Million to Accelerate Commercialization of Its Innovative Tankless Inhaled Nitric Oxide Delivery SystemJanuary 9, 2023 | cbsnews.comUSDA approves vaccine for honeybees, biotech company saysJanuary 4, 2023 | marketwatch.comBioreactors and Fermenters Market 2023 Expected to Witness the Highest Revenue Growth Over Forecast to 2028December 28, 2022 | forbes.comBrickell BiotechDecember 18, 2022 | marketwatch.comNuclear Receptor ROR-Gamma Market : Industry Analysis 2023 To 2028 based on Sales, Revenue, Size and ShareDecember 5, 2022 | nz.finance.yahoo.comAtopic Dermatitis Pipeline Appears Robust With 90+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsightSeptember 13, 2022 | finance.yahoo.comFresh Tracks Therapeutics Initiates Multiple Ascending Dose Portion of Phase 1 Study of DYRK1A Inhibitor FRTX-02September 7, 2022 | finance.yahoo.comBrickell Biotech Announces Corporate Rebranding to Fresh Tracks TherapeuticsAugust 11, 2022 | seekingalpha.comBrickell Biotech, Inc. (BBI) CEO Robert Brown on Q2 2022 Results - Earnings Call TranscriptAugust 2, 2022 | benzinga.comBrickell Biotech to Report Second Quarter 2022 Financial Results and Provide a Corporate Update on August 11, 2022July 20, 2022 | finance.yahoo.comBrickell Biotech Regains Compliance with Nasdaq Minimum Bid Price RequirementJuly 6, 2022 | finance.yahoo.comBrickell Biotech to Participate at William Blair Biotech Focus Conference 2022July 1, 2022 | marketwatch.comBrickell Biotech Shares Down 24% After Reverse Stock Split PlansSee More Headlines Receive BBI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Brickell Biotech and its competitors with MarketBeat's FREE daily newsletter. Email Address BBI Company Calendar Last Earnings8/11/2022Today9/24/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Biological Products, Except Diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:BBI CUSIPN/A CIK819050 Webwww.brickellbio.com Phone(720) 505-4755Fax858-646-1150Employees16Year Founded2009Profitability EPS (Most Recent Fiscal Year)($13.52) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-39,470,000.00 Net Margins-643.48% Pretax Margin-643.48% Return on Equity-156.10% Return on Assets-128.23% Debt Debt-to-Equity RatioN/A Current Ratio6.36 Quick Ratio6.36 Sales & Book Value Annual Sales$4.64 million Price / Sales0.61 Cash FlowN/A Price / Cash FlowN/A Book Value$9.75 per share Price / Book0.10Miscellaneous Outstanding Shares2,874,000Free Float2,744,000Market Cap$2.82 million OptionableNot Optionable Beta0.02 Social Links 10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesMr. Reginald L. Hardy M.B.A. (Age 64)R.Ph., Co-Founder & Chairman Comp: $76.83kAttorney Robert Busard Brown (Age 60)CEO & Director Comp: $816.73kMr. Andrew D. Sklawer (Age 38)Co-Founder, Pres, COO & Sec. Comp: $559.58kMr. Deepak Chadha M.B.A. (Age 52)M.S., MBA, MS, RAC, Chief R&D Officer Comp: $543.59kMr. Albert Nicholas Marchio II (Age 70)CFO and Principal Accounting & Financial Officer Mr. David R. Mcavoy J.D. (Age 59)Gen. Counsel & Chief Compliance Officer Mr. Gary S. Walker (Age 62)Chief Marketing Officer Aron Aizenstat M.B.A.P.M.P., VP of Corp. Devel. & OperationsMs. Sue FattorHead of Human ResourceMs. Nancy SerettaVP & Head of Clinical OperationsMore ExecutivesKey CompetitorsRubius TherapeuticsNASDAQ:RUBYIgnyte AcquisitionNASDAQ:IGNYScinai ImmunotherapeuticsNASDAQ:SCNISQZ BiotechnologiesNYSE:SQZKiromic BioPharmaNASDAQ:KRBPView All Competitors BBI Stock - Frequently Asked Questions How have BBI shares performed in 2023? Brickell Biotech's stock was trading at $1.50 on January 1st, 2023. Since then, BBI stock has decreased by 34.7% and is now trading at $0.98. View the best growth stocks for 2023 here. How were Brickell Biotech's earnings last quarter? Brickell Biotech, Inc. (NASDAQ:BBI) released its quarterly earnings results on Thursday, August, 11th. The company reported ($0.01) earnings per share for the quarter, beating analysts' consensus estimates of ($1.48) by $1.47. Brickell Biotech had a negative net margin of 643.48% and a negative trailing twelve-month return on equity of 156.10%. During the same period in the previous year, the business earned ($7.21) earnings per share. When did Brickell Biotech's stock split? Brickell Biotech shares reverse split on the morning of Tuesday, July 5th 2022. The 1-45 reverse split was announced on Tuesday, July 5th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, July 5th 2022. An investor that had 100 shares of stock prior to the reverse split would have 2 shares after the split. What other stocks do shareholders of Brickell Biotech own? Based on aggregate information from My MarketBeat watchlists, some companies that other Brickell Biotech investors own include Sorrento Therapeutics (SRNE), VBI Vaccines (vbiv), Jaguar Health (JAGX), Miragen Therapeutics (MGEN), Acasti Pharma (ACST), Allena Pharmaceuticals (ALNA), Aileron Therapeutics (ALRN), Amarin (AMRN), Fortress Biotech (FBIO) and iBio (IBIO). What is Brickell Biotech's stock symbol? Brickell Biotech trades on the NASDAQ under the ticker symbol "BBI." How do I buy shares of Brickell Biotech? Shares of BBI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Brickell Biotech's stock price today? One share of BBI stock can currently be purchased for approximately $0.98. How much money does Brickell Biotech make? Brickell Biotech (NASDAQ:BBI) has a market capitalization of $2.82 million and generates $4.64 million in revenue each year. The company earns $-39,470,000.00 in net income (profit) each year or ($13.52) on an earnings per share basis. How can I contact Brickell Biotech? Brickell Biotech's mailing address is 5777 CENTRAL AVENUE SUITE 102, BOULDER CO, 80301. The official website for the company is www.brickellbio.com. The company can be reached via phone at (720) 505-4755, via email at ir@brickellbio.com, or via fax at 858-646-1150. This page (NASDAQ:BBI) was last updated on 9/24/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Brickell Biotech, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.